These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 8192579)

  • 21. Computational toxicology: Its essential role in reducing drug attrition.
    Naven RT; Louise-May S
    Hum Exp Toxicol; 2015 Dec; 34(12):1304-9. PubMed ID: 26614820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers in drug discovery and development.
    Bakhtiar R
    J Pharmacol Toxicol Methods; 2008; 57(2):85-91. PubMed ID: 18024093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MutAIT: an online genetic toxicology data portal and analysis tools.
    Avancini D; Menzies GE; Morgan C; Wills J; Johnson GE; White PA; Lewis PD
    Mutagenesis; 2016 May; 31(3):323-8. PubMed ID: 26208916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computer modeling and computational toxicology in new chemical and pharmaceutical product development.
    Hall AH
    Toxicol Lett; 1998 Dec; 102-103():623-6. PubMed ID: 10022324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulatory toxicology: objectives and tasks defined by the working group of the German society of experimental and clinical pharmacology and toxicology.
    Schwenk M; Werner M; Younes M
    Toxicol Lett; 2002 Feb; 126(3):145-53. PubMed ID: 11814699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular clinical safety intelligence: a system for bridging clinically focused safety knowledge to early-stage drug discovery - the GSK experience.
    Vanderwall DE; Yuen N; Al-Ansari M; Bailey J; Fram D; Green DV; Pickett S; Vitulli G; Luengo JI; Almenoff JS
    Drug Discov Today; 2011 Aug; 16(15-16):646-53. PubMed ID: 21601652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies.
    Aardema MJ; MacGregor JT
    Mutat Res; 2002 Jan; 499(1):13-25. PubMed ID: 11804602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 1984 Stokinger lecture. Some questions and opinions on issues in toxicology and risk assessment.
    Weil CS
    Am Ind Hyg Assoc J; 1984 Oct; 45(10):663-70. PubMed ID: 6496314
    [No Abstract]   [Full Text] [Related]  

  • 29. A survey of the Predictive Toxicology Challenge 2000-2001.
    Helma C; Kramer S
    Bioinformatics; 2003 Jul; 19(10):1179-82. PubMed ID: 12835259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of the threshold of toxicological concern concept when applied to pharmaceutical manufacturing operations intended for short-term clinical trials.
    Bercu JP; Dolan DG
    Regul Toxicol Pharmacol; 2013 Feb; 65(1):162-7. PubMed ID: 22732128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.
    Ganter B; Tugendreich S; Pearson CI; Ayanoglu E; Baumhueter S; Bostian KA; Brady L; Browne LJ; Calvin JT; Day GJ; Breckenridge N; Dunlea S; Eynon BP; Furness LM; Ferng J; Fielden MR; Fujimoto SY; Gong L; Hu C; Idury R; Judo MS; Kolaja KL; Lee MD; McSorley C; Minor JM; Nair RV; Natsoulis G; Nguyen P; Nicholson SM; Pham H; Roter AH; Sun D; Tan S; Thode S; Tolley AM; Vladimirova A; Yang J; Zhou Z; Jarnagin K
    J Biotechnol; 2005 Sep; 119(3):219-44. PubMed ID: 16005536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can systems toxicology identify common biomarkers of non-genotoxic carcinogenesis?
    Plant N
    Toxicology; 2008 Dec; 254(3):164-9. PubMed ID: 18674585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The expanding role of predictive toxicology: an update on the (Q)SAR models for mutagens and carcinogens.
    Benigni R; Netzeva TI; Benfenati E; Bossa C; Franke R; Helma C; Hulzebos E; Marchant C; Richard A; Woo YT; Yang C
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2007; 25(1):53-97. PubMed ID: 17365342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mouse versus the rat in carcinogen bioassays.
    Clayson DB
    Fundam Appl Toxicol; 1984 Jun; 4(3 Pt 1):499-501. PubMed ID: 6745541
    [No Abstract]   [Full Text] [Related]  

  • 35. The use of pharmacokinetics as an interpretive and predictive tool in chemical toxicology testing and risk assessment: a position paper on the appropriate use of pharmacokinetics in chemical toxicology.
    Frantz SW; Beatty PW; English JC; Hundley SG; Wilson AG
    Regul Toxicol Pharmacol; 1994 Jun; 19(3):317-37. PubMed ID: 8090955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Call to curb lab tests on dogs.
    Turner M
    Nature; 2011 Jun; 474(7353):551. PubMed ID: 21720337
    [No Abstract]   [Full Text] [Related]  

  • 37. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
    Buckley LA; Dorato MA
    Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The international harmonisation of guidelines in the future: a viewpoint from the industry.
    Ekman L
    Toxicol Lett; 1998 Dec; 102-103():551-5. PubMed ID: 10022311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The specialty of medical toxicology: beyond poisonous arrows and activated charcoal.
    Liebelt EL
    Clin Pharmacol Ther; 2010 Sep; 88(3):298-301. PubMed ID: 20725078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic toxicity and carcinogenicity guidelines.
    Page NP
    J Environ Pathol Toxicol; 1977; 1(2):161-82. PubMed ID: 553129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.